相关实验视频
Updated: May 7, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
在非酒精性脂肪肝疾病中使用细胞素18:价值和应用
Yuan Wu1,2, Jing Zhou2, Jun Zhang2
1School of Medicine, The 2nd Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
早期发现非酒精性脂肪性肝病 (NAFLD) 是至关重要的. 细胞激素18 (CK18) 显示为非侵入性NAFLD诊断和监测的生物标志物,有助于及时进行生活方式干预.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 生物标志物发现发现
- 代谢疾病 代谢疾病
背景情况:
- 非酒精性脂肪肝 (NAFLD) 是一种普遍存在的全球代谢障碍.
- 目前用于NAFLD的诊断方法在准确性,成本和安全性方面存在局限性.
- 生活方式的改变是NAFLD管理的基石,强调了早期检测的必要性.
研究的目的:
- 评估Cytokeratin 18 (CK18) 作为非酒精性脂肪肝疾病 (NAFLD) 的潜在生物标志物.
- 探索CK18在诊断NAFLD及其阶段,特别是非酒精性脂肪肝炎 (NASH) 中的实用性.
- 评估CK18在监测NAFLD治疗疗效和预测疾病相关风险方面的作用.
主要方法:
- 对CK18作为NAFLD生物标志物的现有文献的审查.
- 在肝脏脂肪积累的背景下,分析CK18与细胞亡和细胞死亡的相关性.
- 在NAFLD患者中评估CK18的诊断和预后能力.
主要成果:
- 在NAFLD中,由于肝脏脂肪积累,CK18是一种亡标记物,被释放到血液中.
- CK18水平与NAFLD进展相关,包括NASH的识别.
- CK18是评估治疗有效性和疾病风险的有价值指标.
结论:
- CK18提供了一种非侵入性的方法来监测NAFLD病理状况.
- 将CK18纳入诊断标准可以提高NAFLD早期检测和干预.
- CK18是改善NAFLD管理策略的一个有前途的工具.
更多相关视频
08:41Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
Published on: March 24, 2023
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
相关概念视频
Liver Histology
Hepatocytes perform a variety of essential functions. They secrete...
Liver Physiology
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Cirrhosis I: Introduction
Cirrhosis II: Pathophysiology